Nanjing Medlander Medical Technology (SH:688273) Hua Yuan Zheng Quan·2025-12-07 14:03Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company has signed a strategic cooperation agreement with Yijiahe, focusing on the deep integration of brain-computer interface and intelligent robot technology, aiming to expand new applications in intelligent health care, emotional interaction, and health management [6] - The company's main business shows steady growth, with a revenue of 344 million yuan in the first three quarters of 2025, representing a year-on-year increase of 4.01% [6] - The company is increasing its R&D investment to support expected performance growth, with a gross margin of 70.05% in the first three quarters of 2025 [6] Financial Summary - Revenue forecast for 2025 is 5.07 billion yuan, with a year-on-year growth rate of 19.51% [5] - Net profit attributable to shareholders is expected to be 1.17 billion yuan in 2025, with a year-on-year growth rate of 14.89% [5] - The company's P/E ratio is projected to be 30.15 in 2025 [5]